Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia

NCT02040883 is registered in ClinicalTrials.gov with Qingyun Yin as lead sponsor.

NCT NCT02040883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02040883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia
Lead sponsor
Qingyun Yin
Phase
Phase 4
Overall status
Unknown status
Start date
February 28, 2014
Completion date
December 31, 2014
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia